Welcome to our dedicated page for Becton, Dickinson and Co. news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton, Dickinson and Co. stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology firm committed to advancing healthcare through the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Established in 1897, BD's mission is to enhance medical discovery, diagnostics, and care delivery. The company's extensive product portfolio serves healthcare institutions, physicians, life science researchers, and others across the globe.
BD is noted for being the world’s largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. The company also excels in producing pre-filled devices, diagnostic instruments, and reagents. Furthermore, BD offers sophisticated flow cytometry and cell-imaging systems. BD Medical represents nearly half of the company's total business, while BD Life Sciences and BD Interventional contribute 27% and 24% of the 2023 revenue, respectively. Impressively, international revenue accounts for 43% of the company's business.
Recent achievements and projects underscore BD's commitment to innovation and sustainability. The company recently collaborated with health care institutions in Denmark to explore recycling used blood collection tubes, achieving significant environmental advancements without compromising safety or quality.
In a pivotal development, BD announced the global commercial release of new cell sorters, enabling researchers in fields such as cell biology, cancer research, and immunology to gain new insights. The BD FACSDiscover™ S8 Cell Sorters incorporate groundbreaking technologies like BD CellView™ Image Technology and BD SpectralFX™ Technology, significantly enhancing real-time imaging and spectral flow cytometry.
BD also reported robust financial performance for the second quarter of fiscal 2024, highlighting strong operating margins and cash flow. This success led to an optimistic outlook and an increased earnings guidance, demonstrating the company’s resilience and strategic execution.
Further solidifying its market position, BD is set to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This acquisition expands BD’s portfolio in smart connected care solutions, leveraging advanced AI algorithms for better patient outcomes and adding significant value to its operations.
With a presence in almost every country and a workforce of over 70,000 employees, BD remains dedicated to advancing the world of health. The company works closely with customers and partners globally to address complex health challenges, enhance clinical outcomes, and expand access to healthcare.
BD has received 510(k) clearance from the FDA for its BD COR™ MX instrument, enhancing STI diagnostics capabilities. The first assay available detects Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. This system automates laboratory workflows, enabling the processing of 1,700 specimens and delivering up to 1,000 results in 24 hours. By reducing manual interactions, it aims to alleviate staff workloads, especially critical amidst ongoing healthcare staffing challenges. Future assays for women's health and other indications are in development.
Babson Diagnostics and BD (Becton, Dickinson and Company) have expanded their partnership to enhance blood sample collection, making it more patient-centered and less invasive. Announced on May 11, 2022, the collaboration aims to enable at-home blood sample collection and broaden test capabilities to include pediatric diagnostics. This initiative, developed since 2019, leverages advanced capillary collection technology, requiring only a fraction of the blood volume compared to traditional methods. The companies aim to improve patient compliance by providing a more convenient testing experience.
BD (Becton, Dickinson and Company) reported a revenue increase of 2.1% to $5.0 billion for Q2 FY2022, aided by a base revenue growth of 8.2%. However, COVID-only testing revenues fell to $214 million from $474 million. GAAP diluted EPS rose 59.6% to $1.50, while adjusted EPS was slightly down at $3.18. The company updated its fiscal 2022 guidance, projecting revenues between $19.6 and $19.8 billion, and adjusted EPS between $12.85 and $13.00. This reflects an increase in base business currency-neutral revenue growth estimates to 6.75%-7.75% and an anticipated headwind from foreign exchange.
BD (Becton, Dickinson and Company) has introduced its Scientific Advisory Board (SAB), comprising leading experts in health care, science, and technology. The board will provide insights on BD's innovation pipeline, technology capabilities, and emerging trends in the medical field. CEO Tom Polen stated that the SAB aims to enhance patient outcomes and drive growth through impactful innovations. Notable members include John DeFord from Purdue University and Claire Fraser from the University of Maryland. This strategic move is part of BD's commitment to lead in advancing health care technologies.
BD (Becton, Dickinson and Company) will present at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 12:00 p.m. Pacific Time. Investors can access the live webcast from BD's investor relations website, with a replay available post-event. BD, a leading global medical technology firm, is dedicated to advancing health through innovative technology and solutions, supporting healthcare providers and improving patient outcomes. BD boasts a workforce of 75,000 and operates globally to address significant health challenges.
BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.87 per common share, set to be paid on June 30, 2022. Shareholders on record by June 9, 2022 will receive this payment, resulting in an annual dividend rate of $3.48 per share. This decision reflects the company's commitment to return value to its shareholders while maintaining a strong presence in global medical technology.
BD (Becton, Dickinson and Company) (NYSE: BDX) announced the launch of BD Horizon RealYellow™ 586 Reagents, a breakthrough in flow cytometry developed using novel dye technology and AI guidance. These reagents enable improved data resolution, facilitating deeper biological insights in oncology, autoimmune disorders, and infectious diseases. The reagents support both conventional and spectral flow cytometry, allowing researchers to analyze more markers per sample. With their global availability, BD aims to enhance research capabilities and accelerate drug development.
BD (Becton, Dickinson and Company) has established the Sustainable Medical Technology Institute to enhance its environmental sustainability efforts. This initiative targets three key areas: sustainable product design, sterilization technologies, and materials of concern. By leveraging interdisciplinary expertise, BD aims to reduce the environmental impact of its products while supporting its 2030+ environmental, social, and governance (ESG) commitments. The institute will collaborate globally and set environmental criteria for new products to better meet sustainability needs.
BD (Becton, Dickinson and Company) will report its financial results for the second quarter of fiscal year 2022 on May 5, 2022, at approximately 6:30 a.m. ET. The announcement will include summary financial information for the quarter ending March 31, 2022. Management will conduct a conference call at 8 a.m. ET on the same day to discuss results and operational strategy.
Investors can access the news release and presentation materials on the company’s investor relations website.
BD (Becton, Dickinson and Company) has successfully completed its spinoff of Embecta Corp, which now operates independently, focusing on diabetes care. Shareholders received one share of Embecta for every five shares of BD held as of March 22, 2022. This strategic move aligns with BD's 2025 plan to enhance long-term shareholder value by allowing both companies to concentrate on their core businesses. Embecta aims to further develop diabetes injection devices, while BD continues to lead in medical and life sciences sectors.
FAQ
What is the current stock price of Becton, Dickinson and Co. (BDX)?
What is the market cap of Becton, Dickinson and Co. (BDX)?
What does Becton, Dickinson and Company (BD) specialize in?
What are BD's main business segments?
What recent projects has BD undertaken?
How much of BD's revenue comes from international markets?
What significant acquisition has BD announced recently?
How many employees does BD have?
Where can I find more information about BD's financial performance?
What is the significance of the BD FACSDiscover™ S8 Cell Sorters?
Which regulatory body recently issued a safety communication regarding syringes?
What is BD's approach to sustainability?
